ELIAS Animal Health Blog
Read the latest news and updates from ELIAS Animal Health
ELIAS Animal Health Expands Manufacturing Capacity Ahead of Product Approval and Pipeline Expansion
OLATHE, Kan., April 30, 2024 /PRNewswire/ -- ELIAS Animal Health, a leading companion animal cancer therapeutics company, is expanding its [...]
ELIAS Animal Health Appoints Chief Revenue Officer; Launches Fundraising Round to Support Commercialization and Development of Innovative Canine Cancer Therapies
Experienced executive will lead launch of the first USDA-approved immunotherapy for the treatment of bone cancer in dogs OLATHE, Kan., [...]
USDA Agrees Clinical Trial Data for the ELIAS Cancer Immunotherapy (ECI®) Demonstrates Reasonable Expectation of Efficacy for the Treatment of Bone Cancer in Dogs
First-in-class adoptive cell therapy for treatment of osteosarcoma, a deadly form of bone cancer in dogs OLATHE, Kan., Jan. 17, [...]
New Clinical Trial Will Evaluate Combination Therapy to Treat Canine Lymphoma
After successfully concluding a clinical trial for canine osteosarcoma, ELIAS Animal Health is focused on continuing to push forward in [...]
ELIAS Animal Health Research Demonstrates Cancer-Killing Capabilities of Its Activated T Cell Immunotherapy
In vitro study of the ELIAS Cancer Immunotherapy (ECI®) showed personalized T cell immunotherapy initiated a significant immune response [...]
ELIAS Animal Health Expands Scientific Advisory Board
Nov. 23, 2021 — ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, [...]
ELIAS Animal Health In-Licenses Oncolytic Vaccinia Virus Treatment for Pet Animals from Genelux Corporation
Agreement grants ELIAS Animal Health the worldwide right to development and commercialization of V-VET1 for the diagnosis, prevention and treatment [...]